Cargando…
Immunologic treatment failure among HIV-infected adult patients in Jiangsu province, China
The National Free Antiretroviral Treatment Program was implemented in Jiangsu Province, China in 2005. We conducted a retrospective, open cohort study to determine treatment failure rates and associated risk factors. Data were obtained from the national web-based antiretroviral treatment database. W...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318988/ https://www.ncbi.nlm.nih.gov/pubmed/28220792 http://dx.doi.org/10.1038/srep42381 |
_version_ | 1782509292775014400 |
---|---|
author | Qiu, Tao Ding, Ping Fu, Gengfeng Huan, Xiping Xu, Xiaoqin Zhang, Zhi Liu, Xiaoyan Yang, Haitao Mandel, Jeff Wei, Chongyi McFarland, Willi Yan, Hongjing |
author_facet | Qiu, Tao Ding, Ping Fu, Gengfeng Huan, Xiping Xu, Xiaoqin Zhang, Zhi Liu, Xiaoyan Yang, Haitao Mandel, Jeff Wei, Chongyi McFarland, Willi Yan, Hongjing |
author_sort | Qiu, Tao |
collection | PubMed |
description | The National Free Antiretroviral Treatment Program was implemented in Jiangsu Province, China in 2005. We conducted a retrospective, open cohort study to determine treatment failure rates and associated risk factors. Data were obtained from the national web-based antiretroviral treatment database. WHO criteria were used to define immunologic treatment failure. Kaplan-Meier methods were used to determine treatment failure rates and Cox proportional hazards modeling was used to identify risk factors. A total of 5,083 (87.8%) having at least one CD4 cell count measure were included from 2005 to 2013. Overall, 30.4% had immunologic treatment failure with cumulative treatment failure rates increasing to 50.5% at month 60 and 64.1% at month 90. Factors predicting treatment failure included being treated in the Centers for Disease Control and Prevention system (HR 1.69, 95% CI 1.14–2.50, p = 0.009) or jail hospital (HR 1.20, 95% CI 1.08–1.34, p = 0.001), and having a baseline CD4 count >350 cells/uL (HR 2.37, 95% CI 1.94–2.89. p < 0.001). Immunologic treatment failure was moderate to substantial among treated HIV patients. Providing second-line regimens and shifting treatment providers to professional hospitals should be considered to consolidate gains in averting morbidity and mortality. |
format | Online Article Text |
id | pubmed-5318988 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-53189882017-02-24 Immunologic treatment failure among HIV-infected adult patients in Jiangsu province, China Qiu, Tao Ding, Ping Fu, Gengfeng Huan, Xiping Xu, Xiaoqin Zhang, Zhi Liu, Xiaoyan Yang, Haitao Mandel, Jeff Wei, Chongyi McFarland, Willi Yan, Hongjing Sci Rep Article The National Free Antiretroviral Treatment Program was implemented in Jiangsu Province, China in 2005. We conducted a retrospective, open cohort study to determine treatment failure rates and associated risk factors. Data were obtained from the national web-based antiretroviral treatment database. WHO criteria were used to define immunologic treatment failure. Kaplan-Meier methods were used to determine treatment failure rates and Cox proportional hazards modeling was used to identify risk factors. A total of 5,083 (87.8%) having at least one CD4 cell count measure were included from 2005 to 2013. Overall, 30.4% had immunologic treatment failure with cumulative treatment failure rates increasing to 50.5% at month 60 and 64.1% at month 90. Factors predicting treatment failure included being treated in the Centers for Disease Control and Prevention system (HR 1.69, 95% CI 1.14–2.50, p = 0.009) or jail hospital (HR 1.20, 95% CI 1.08–1.34, p = 0.001), and having a baseline CD4 count >350 cells/uL (HR 2.37, 95% CI 1.94–2.89. p < 0.001). Immunologic treatment failure was moderate to substantial among treated HIV patients. Providing second-line regimens and shifting treatment providers to professional hospitals should be considered to consolidate gains in averting morbidity and mortality. Nature Publishing Group 2017-02-21 /pmc/articles/PMC5318988/ /pubmed/28220792 http://dx.doi.org/10.1038/srep42381 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Qiu, Tao Ding, Ping Fu, Gengfeng Huan, Xiping Xu, Xiaoqin Zhang, Zhi Liu, Xiaoyan Yang, Haitao Mandel, Jeff Wei, Chongyi McFarland, Willi Yan, Hongjing Immunologic treatment failure among HIV-infected adult patients in Jiangsu province, China |
title | Immunologic treatment failure among HIV-infected adult patients in Jiangsu province, China |
title_full | Immunologic treatment failure among HIV-infected adult patients in Jiangsu province, China |
title_fullStr | Immunologic treatment failure among HIV-infected adult patients in Jiangsu province, China |
title_full_unstemmed | Immunologic treatment failure among HIV-infected adult patients in Jiangsu province, China |
title_short | Immunologic treatment failure among HIV-infected adult patients in Jiangsu province, China |
title_sort | immunologic treatment failure among hiv-infected adult patients in jiangsu province, china |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318988/ https://www.ncbi.nlm.nih.gov/pubmed/28220792 http://dx.doi.org/10.1038/srep42381 |
work_keys_str_mv | AT qiutao immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina AT dingping immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina AT fugengfeng immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina AT huanxiping immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina AT xuxiaoqin immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina AT zhangzhi immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina AT liuxiaoyan immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina AT yanghaitao immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina AT mandeljeff immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina AT weichongyi immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina AT mcfarlandwilli immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina AT yanhongjing immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina |